Novo Nordisk and Eli Lilly will dominate the weight loss drug market, experts say

The effect of the drugs on co-morbidities will also be decisive for competition in the market.
Photo: Staff
Photo: Staff
by marketwire

Novo Nordisk and Eli Lilly will in the future dominate the market for weight loss drugs when it comes to the ability to create weight loss, according to experts. Decisive for the competition in the market will also be the effect of the drugs on the complications of obesity and the possibilities of creating individualized treatment, Danish business newspaper Børsen reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading